Mibefradil and an effective formulary system.
作者信息
Vermeulen L C, Dunham D B
出版信息
Am J Health Syst Pharm. 1998 Sep 15;55(18):1934-5. doi: 10.1093/ajhp/55.18.1934.
PMID:9784776
Abstract
摘要
相似文献
1
Mibefradil and an effective formulary system.
Am J Health Syst Pharm. 1998 Sep 15;55(18):1934-5. doi: 10.1093/ajhp/55.18.1934.
2
What lessons can be learnt from withdrawal of mibefradil from the market?从米贝拉地尔撤市事件中可以吸取哪些教训？
Lancet. 1998 Jun 20;351(9119):1829-30. doi: 10.1016/s0140-6736(05)78800-0.
3
Mibefradil withdrawn from the market.
Ann Pharmacother. 1998 Jul-Aug;32(7-8):841. doi: 10.1345/aph.17356.
4
From the Food and Drug Administration.
JAMA. 1998 Feb 4;279(5):346.
5
Withdrawal of Posicor from market.波生坦退出市场。
Circulation. 1998 Sep 1;98(9):831-2. doi: 10.1161/01.cir.98.9.831.
6
Comment: mibefradil, a new class of calcium-channel antagonists.评论：米贝拉地尔，一类新型钙通道拮抗剂。
Ann Pharmacother. 1998 Dec;32(12):1372. doi: 10.1345/aph.16441a.
7
The withdrawal of mibefradil (Posicor).
Adverse Drug React Toxicol Rev. 1998 Jun-Sep;17(2-3):59-60.
8
Mibefradil--a new calcium-channel blocker.米贝拉地尔——一种新型钙通道阻滞剂。
Med Lett Drugs Ther. 1997 Nov 7;39(1013):103-5.
9
Mibefradil (Posicor) induced sinus arrest.
Aust N Z J Med. 1998 Dec;28(6):836-7. doi: 10.1111/j.1445-5994.1998.tb01567.x.
10
[Induction of bradycardia by mibefradil in antihypertensive combination therapy].
Dtsch Med Wochenschr. 1998 Apr 24;123(17):547.
Zotero 插件